drugset / Trial / NCT04018872

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

NCT04018872

Phase 2 Recruiting 78 enrolled Dallas VA Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Esophageal cancer, which has a low 5-year overall survival rate for all stages (\<20%) , is increasing in incidence. Previous studies have shown that the Hedgehog (Hh) and AKT signaling pathways are activated in a significant proportion of esophageal cancers. Itraconazole, a widely used anti-fungal medication, has been shown to inhibit various pathways involved in esophageal cancer tumorigenesis including Hh and AKT. In this phase II clinical trial, the investigators aim to evaluate the effect of itraconazole as a neoadjuvant therapy following standard of care chemoradiation in the treatment of locoregional esophageal and gastroesophageal junction carcinomas.

Timeline

Start
2019-06-24
Primary completion
2026-06-24
Completion
2026-09-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 300 mg Oral